Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Change in Cash (2024 - 2026)

Maze Therapeutics recorded quarterly Change in Cash of $9.5 million in Q1 2026, up 107.46% quarter-over-quarter from -$127.5 million in Q4 2025, and down 90.24% year-over-year from $97.6 million in Q1 2025.

Maze Therapeutics' Change in Cash history runs 3 years deep, the most recent figure standing at $9.5 million for Q1 2026.

  • In Q1 2026, Change in Cash fell 90.24% year-over-year to $9.5 million; the TTM figure through Mar 2026 stood at -$95.6 million (down 136.17% YoY), while the FY2025 annual figure was -$7.6 million, down 104.51% from the prior year.
  • Change in Cash came in at $9.5 million for Q1 2026 at Maze Therapeutics, up from -$127.5 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $145.0 million in Q2 2024 to a low of -$127.5 million in Q4 2025.
  • A 3-year average of $18.8 million and a median of $9.5 million in 2026 frame the typical range for Change in Cash.
  • On a YoY basis, Change in Cash climbed as much as 11178.96% in 2025 and fell as far as 370.16% in 2025.
  • Maze Therapeutics' Change in Cash stood at $47.2 million in 2024, then tumbled by 370.16% to -$127.5 million in 2025, then soared by 107.46% to $9.5 million in 2026.
  • According to Business Quant data, Change in Cash over the past three periods registered $9.5 million, -$127.5 million, and $52.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.44 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 623.00 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.44 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 417.10 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -153.10 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 53.61 Mn
10 Maze Therapeutics 1.37 Bn 1.37 Bn 18.21 Mn 9.52 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 9.52 Mn
Dec 31, 2025 -127.53 Mn
Sep 30, 2025 52.23 Mn
Jun 30, 2025 -29.83 Mn
Mar 31, 2025 97.56 Mn
Dec 31, 2024 47.21 Mn
Sep 30, 2024 -25.46 Mn
Jun 30, 2024 145.04 Mn
Mar 31, 2024 865,000.00